Sign Up
Stories
AEON Biopharma Advances Migraine Treatments
Share
AB Science's Medical Breakthrough Webcas...
ABBio Innovates Antibody Development
ABIONYX Pharma Files 2023 Document
ACTICOR BIOTECH: Financial Report Postpo...
ADOCIA Files 2023 Registration Document
ANJESO Drug Insight and Market Forecast
Overview
API
AEON Biopharma progresses with ABP-450 migraine programs, secures $15M private placement for research and development endeavors.
Ask a question
How does the private placement of $15 million reflect investor confidence in AEON Biopharma's research and development efforts?
How might the FDA alignment impact the timeline for ABP-450's availability?
What potential benefits could ABP-450 bring to patients suffering from chronic migraines?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Coverage